Perancangan Radiofarmaka Teranostik Kanker Penargetan Transporter Asam Amino Tipe-L1: Simulasi Docking Molekuler
DOI:
https://doi.org/10.22437/chp.v9i2.48053Kata Kunci:
Chelating agent, LAT1, pan-cancer, Molecular Operating Environment (MOE), theranostic, radiopharmaceuticalAbstrak
Abstract. L-type amino acid transporter 1 (LAT1) is a potential pan-cancer theranostic molecular target. The LAT1 inhibitory potencies of eight theranostic radiopharmaceuticals designed based on a potent LAT1 inhibitor ADPB (in vitro pIC50 6.19), were estimated in molecular docking simulations. The designs comprised ADPB as a carrier molecule with/without 6-aminohexanoic acid (Ahx) linker, a chelating agent, and a radiometal (68Ga or 177Lu). JPH203, the most potent LAT1 inhibitor (pIC50 7.22), was utilized as a benchmark compound. A set of known LAT1 ligands (n = 15) were first docked into LAT1 to build the docking protocol. Adding a linker improved the LAT1 inhibitory potency of DOTA-conjugated and NODAGA-conjugated ADPB-based theranostic radiopharmaceutical designs. 177Lu-DOTA-Ahx-ADPB has the exceptional LAT1 inhibitory potency (pIC50 51.55 ± 17.06) while 177Lu-DOTA-ADPB, its non-linker counterpart, has LAT1 inhibitory potency significantly higher than the native JPH203. Both 177Lu-DOTA-Ahx-ADPB and 177Lu-DOTA-ADPB have strong bonds with key amino acids on the LAT1 binding pocket, particularly Asn258, Tyr259, and the gating residue Phe252. Our findings provide a quantitative and illustrative understanding of the LAT1 inhibitory potency of LAT1-targeting theranostic radiopharmaceutical designs relevant to the rational design of pan-cancer radiotheranostic drugs.
Keywords: LAT1, pan-cancer, theranostic radiopharmaceutical, MOE, chelating agent, gallium-68, lutetium-177.
Unduhan
Referensi
[1]. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 2021; 71:209-49. doi: DOI: 10.3322/caac.21660.
[2]. Roesch F, Martin M. Radiometal-theranostics: the first 20 years*. Journal of Radioanalytical and Nuclear Chemistry 2022; DOI: 10.1007/s10967-022-08624-3.
[3]. Bodei L, Herrmann K, Schöder H, Scott AM, Lewis JS. Radiotheranostics in oncology: current challenges and emerging opportunities. Nature Reviews Clinical Oncology 2022; DOI: 10.1038/s41571-022-00652-y.
[4]. Sollini M, Kirienko M, Gelardi F, Fiz F, Gozzi N, Chiti A. State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis. European Journal of Nuclear Medicine and Molecular Imaging 2021; 48:4396-414. doi: DOI: 10.1007/s00259-021-05475-0.
[5]. Buck AK, Haug A, Dreher N, Lambertini A, Higuchi T, Lapa C, et al. Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms Using 68Ga-Pentixafor PET. Journal of Nuclear Medicine 2022; 63:1687. doi: DOI: 10.2967/jnumed.121.263693.
[6]. Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Seminars in Cancer Biology 2005; 15:254-66. doi: DOI: 10.1016/j.semcancer.2005.04.005.
[7]. Kanai Y. Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics. Pharmacology & therapeutics 2021; 107964. doi: DOI: 10.1016/j.pharmthera.2021.10796
[8]. Broer S. Amino Acid Transporters as Targets for Cancer Therapy: Why, Where, When, and How. International journal of molecular sciences 2020; 21:DOI: 10.3390/ijms21176156.
[9]. Lopes C, Pereira C, Medeiros R. ASCT2 and LAT1 Contribution to the Hallmarks of Cancer: From a Molecular Perspective to Clinical Translation. Cancers (Basel) 2021; 13:DOI: 10.3390/cancers13020203.
[10]. Achmad A, Bhattarai A, Yudistiro R, Heryanto YD, Higuchi T, Tsushima Y. The diagnostic performance of 18F-FAMT PET and 18F-FDG PET for malignancy detection: a meta-analysis. BMC Medical Imaging 2017; 17:66. doi: DOI: 10.1186/s12880-017-0237-1.
[11]. Kim M, Achmad A, Higuchi T, Arisaka Y, Yokoo H, Yokoo S, et al. Effects of intratumoral inflammatory process on 18F-FDG uptake: pathologic and comparative study with 18F-fluoro-alpha-methyltyrosine PET/CT in oral squamous cell carcinoma. Journal of Nuclear Medicine 2015; 56:16-21. doi: DOI: 10.2967/jnumed.114.144014.
[12]. Hanaoka H, Ohshima Y, Yamaguchi A, Suzuki H, Ishioka NS, Higuchi T, et al. Novel 18F-labeled α-methyl-phenylalanine derivative with high tumor accumulation and ideal pharmacokinetics for tumor-specific imaging. Molecular Pharmaceutics 2019; 16:3609-16. doi: DOI: 10.1021/acs.molpharmaceut.9b00446.
[13]. Nozaki S, Nakatani Y, Mawatari A, Hume WE, Wada Y, Ishii A, et al. First-in-human assessment of the novel LAT1 targeting PET probe 18F-FIMP. Biochemical and Biophysical Research Communications 2022; 596:83-87. doi: DOI: 10.1016/j.bbrc.2022.01.099.
[14]. Watabe T, Ikeda H, Nagamori S, Wiriyasermkul P, Tanaka Y, Naka S, et al. 18F-FBPA as a tumor-specific probe of L-type amino acid transporter 1 (LAT1): a comparison study with 18F-FDG and 11C-Methionine PET. European Journal of Nuclear Medicine and Molecular Imaging 2017; 44:321-31. doi: DOI: 10.1007/s00259-016-3487-1.
[15]. Verhoeven J, Baguet T, Piron S, Pauwelyn G, Bouckaert C, Descamps B, et al. 2-[18F]FELP, a novel LAT1-specific PET tracer, for the discrimination between glioblastoma, radiation necrosis and inflammation. Nuclear Medicine and Biology 2020; 82-83:9-16. doi: DOI: 10.1016/j.nucmedbio.2019.12.002.
[16]. Diagnostic PET/SPECT (Oncology PET) NKO-035 PET clinical research. 2022:
[17]. Watabe T, Naka S, Soeda F, Kamiya T, Sasaki H, Katayama D, et al. First in human dosimetry of 18F-NKO-035: a new PET probe targeting L-type amino acid transporter 1 (LAT1). Journal of Nuclear Medicine 2020; 61:627. doi:
[18]. Singh N, Scalise M, Galluccio M, Wieder M, Seidel T, Langer T, et al. Discovery of potent inhibitors for the large neutral amino acid transporter 1 (LAT1) by structure-based methods. International Journal of Molecular Sciences 2019; 20:27. doi: DOI: 10.3390/ijms20010027.
[19]. Singh N, Villoutreix BO, Ecker GF. Rigorous sampling of docking poses unveils binding hypothesis for the halogenated ligands of L-type Amino acid Transporter 1 (LAT1). Scientific Reports 2019; 9:15061. doi: DOI: 10.1038/s41598-019-51455-8.
[20]. Floresta, G., Keeling, G., Memdouh, S., Meszaros, L., De Rosales, R., & Abbate, V. NHS-Functionalized THP Derivative for Efficient Synthesis of Kit-Based Precursors for 68Ga Labeled PET Probes. Biomedicines, 2021, 9. https://doi.org/10.3390/biomedicines9040367.
[21]. Yan R, Li Y, Müller J, Zhang Y, Singer S, Xia L, et al. Mechanism of substrate transport and inhibition of the human LAT1-4F2hc amino acid transporter. Cell Discovery 2021; 7:16. doi: DOI: 10.1038/s41421-021-00247-4.
[22]. Markowska A, Markowski AR, Jarocka-Karpowicz I. The Importance of 6-Aminohexanoic Acid as a Hydrophobic, Flexible Structural Element. International Journal of Molecular Sciences 2021; 22:12122. doi: DOI: 10.3390/ijms222212122.
[23]. Holik HA, Ibrahim FM, Elaine AA, Putra BD, Achmad A, Kartamihardja AHS. The Chemical Scaffold of Theranostic Radiopharmaceuticals: Radionuclide, Bifunctional Chelator, and Pharmacokinetics Modifying Linker. Molecules 2022; 27:3062. doi: DOI: 10.3390/molecules27103062.
[24]. 24. Achmad A, Lestari S, Holik HA, Rahayu D, Bashari MH, Faried A, et al. Highly Specific L-Type Amino Acid Transporter 1 Inhibition by JPH203 as a Potential Pan-Cancer Treatment. Processes 2021; 9:1170. doi: DOI: 10.3390/pr9071170.
[25]. Yan R, Zhao X, Lei J, Zhou Q. Structure of the human LAT1–4F2hc heteromeric amino acid transporter complex. Nature 2019; 568:127-30. doi: DOI: 10.1038/s41586-019-1011-z.
[26]. Lu J-j, Li P, Yang Y, Wang L, Zhang Y, Zhu J-y, et al. Prognostic value of LAT-1 status in solid cancer: A systematic review and meta-analysis. PLOS ONE 2020; 15:e0233629. doi: DOI: 10.1371/journal.pone.0233629.
[27]. Zhang C, Xu J, Xue S, Ye J. Prognostic Value of L-Type Amino Acid Transporter 1 (LAT1) in Various Cancers: A Meta-Analysis. Molecular Diagnosis & Therapy 2020; 24:523-36. doi: DOI: 10.1007/s40291-020-00470-x.
[28]. Kongpracha P, Nagamori S, Wiriyasermkul P, Tanaka Y, Kaneda K, Okuda S, et al. Structure-activity relationship of a novel series of inhibitors for cancer type transporter L-type amino acid transporter 1 (LAT1). Journal of Pharmacological Sciences 2017; 133:96-102. doi: DOI: 10.1016/j.jphs.2017.01.006.
[29]. Okano N, Naruge D, Kawai K, Kobayashi T, Nagashima F, Endou H, et al. First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors. Investigative New Drugs 2020; DOI: 10.1007/s10637-020-00924-3.
[30]. Okarvi SM, Maecke HR. Chapter Eight - Radiometallo-Labeled Peptides in Tumor Diagnosis and Targeted Radionuclide Therapy. In: van Eldik R, Hubbard CD. Advances in Inorganic ChemistryAcademic Press; 2016:341-96.
[31]. Price EW, Orvig C. Matching chelators to radiometals for radiopharmaceuticals. Chemical Society Reviews 2014; 43:260-90. doi: DOI: 10.1039/c3cs60304k.
[32]. Makris G, Radford LL, Kuchuk M, Gallazzi F, Jurisson SS, Smith CJ, et al. NOTA and NODAGA [99mTc]Tc- and [186Re]Re-Tricarbonyl Complexes: Radiochemistry and First Example of a [99mTc]Tc-NODAGA Somatostatin Receptor-Targeting Bioconjugate. Bioconjugate Chemistry 2018; 29:4040-49. doi: DOI: 10.1021/acs.bioconjchem.8b00670.
[33]. Sudarmanto BSA, Yuswanto A, Susidarti RA, Noegrohati S. Molecular Modeling of Human 3β-Hydroxysteroid Dehydrogenase Type 2: Combined Homology Modeling, Docking and QSAR Approach. Jurnal Ilmu Kefarmasian Indonesia 2017; 7-16%V 15. doi:
[34]. 34. Azam SS, Abbasi SW. Molecular docking studies for the identification of novel melatoninergic inhibitors for acetylserotonin-O-methyltransferase using different docking routines. Theoretical Biology and Medical Modelling 2013; 10:63. doi: DOI: 10.1186/1742-4682-10-63.
[35]. 35. Mansi R, Fani M. Design and development of the theranostic pair 177Lu-OPS201/68Ga-OPS202 for targeting somatostatin receptor expressing tumors. Journal of Labelled Compounds and Radiopharmaceuticals 2019; 62:635-45. doi: DOI: 10.1002/jlcr.3755.
[36]. 36. Rousseau E, Lau J, Zhang Z, Zhang C, Kwon D, Uribe CF, et al. Comparison of biological properties of [177Lu]Lu-ProBOMB1 and [177Lu]Lu-NeoBOMB1 for GRPR targeting. Journal of Labelled Compounds and Radiopharmaceuticals 2020; 63:56-64. doi: DOI: 10.1002/jlcr.
Diterbitkan
Versi
- 2026-01-20 (2)
- 2025-12-31 (1)
